Anti-fibrotic actions of relaxin

C. S. Samuel, S. G. Royce, T. D. Hewitson, K. M. Denton, T. E. Cooney, Robert G Bennett

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Fibrosis refers to the hardening or scarring of tissues that usually results from aberrant wound healing in response to organ injury, and its manifestations in various organs have collectively been estimated to contribute to around 45–50% of deaths in the Western world. Despite this, there is currently no effective cure for the tissue structural and functional damage induced by fibrosis-related disorders. Relaxin meets several criteria of an effective anti-fibrotic based on its specific ability to inhibit pro-fibrotic cytokine and/or growth factor-mediated, but not normal/unstimulated, fibroblast proliferation, differentiation and matrix production. Furthermore, relaxin augments matrix degradation through its ability to up-regulate the release and activation of various matrix-degrading matrix metalloproteinases and/or being able to down-regulate tissue inhibitor of metalloproteinase activity. Relaxin can also indirectly suppress fibrosis through its other well-known (anti-inflammatory, antioxidant, anti-hypertrophic, anti-apoptotic, angiogenic, wound healing and vasodilator) properties. This review will outline the organ-specific and general anti-fibrotic significance of exogenously administered relaxin and its mechanisms of action that have been documented in various non-reproductive organs such as the cardiovascular system, kidney, lung, liver, skin and tendons. In addition, it will outline the influence of sex on relaxin's anti-fibrotic actions, highlighting its potential as an emerging anti-fibrotic therapeutic. Linked Articles: This article is part of a themed section on Recent Progress in the Understanding of Relaxin Family Peptides and their Receptors. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.10/issuetoc.

Original languageEnglish (US)
Pages (from-to)962-976
Number of pages15
JournalBritish Journal of Pharmacology
Volume174
Issue number10
DOIs
StatePublished - Jan 1 2017

Fingerprint

Relaxin
Fibrosis
Wound Healing
Tissue Inhibitor of Metalloproteinases
Western World
Peptide Receptors
Cardiovascular System
Matrix Metalloproteinases
Vasodilator Agents
Tendons
Cicatrix
Intercellular Signaling Peptides and Proteins
Anti-Inflammatory Agents
Up-Regulation
Down-Regulation
Fibroblasts
Antioxidants
Cytokines
Kidney
Lung

ASJC Scopus subject areas

  • Pharmacology

Cite this

Samuel, C. S., Royce, S. G., Hewitson, T. D., Denton, K. M., Cooney, T. E., & Bennett, R. G. (2017). Anti-fibrotic actions of relaxin. British Journal of Pharmacology, 174(10), 962-976. https://doi.org/10.1111/bph.13529

Anti-fibrotic actions of relaxin. / Samuel, C. S.; Royce, S. G.; Hewitson, T. D.; Denton, K. M.; Cooney, T. E.; Bennett, Robert G.

In: British Journal of Pharmacology, Vol. 174, No. 10, 01.01.2017, p. 962-976.

Research output: Contribution to journalArticle

Samuel, CS, Royce, SG, Hewitson, TD, Denton, KM, Cooney, TE & Bennett, RG 2017, 'Anti-fibrotic actions of relaxin', British Journal of Pharmacology, vol. 174, no. 10, pp. 962-976. https://doi.org/10.1111/bph.13529
Samuel CS, Royce SG, Hewitson TD, Denton KM, Cooney TE, Bennett RG. Anti-fibrotic actions of relaxin. British Journal of Pharmacology. 2017 Jan 1;174(10):962-976. https://doi.org/10.1111/bph.13529
Samuel, C. S. ; Royce, S. G. ; Hewitson, T. D. ; Denton, K. M. ; Cooney, T. E. ; Bennett, Robert G. / Anti-fibrotic actions of relaxin. In: British Journal of Pharmacology. 2017 ; Vol. 174, No. 10. pp. 962-976.
@article{1a89338b59e74de2beb8b49c602a2831,
title = "Anti-fibrotic actions of relaxin",
abstract = "Fibrosis refers to the hardening or scarring of tissues that usually results from aberrant wound healing in response to organ injury, and its manifestations in various organs have collectively been estimated to contribute to around 45–50{\%} of deaths in the Western world. Despite this, there is currently no effective cure for the tissue structural and functional damage induced by fibrosis-related disorders. Relaxin meets several criteria of an effective anti-fibrotic based on its specific ability to inhibit pro-fibrotic cytokine and/or growth factor-mediated, but not normal/unstimulated, fibroblast proliferation, differentiation and matrix production. Furthermore, relaxin augments matrix degradation through its ability to up-regulate the release and activation of various matrix-degrading matrix metalloproteinases and/or being able to down-regulate tissue inhibitor of metalloproteinase activity. Relaxin can also indirectly suppress fibrosis through its other well-known (anti-inflammatory, antioxidant, anti-hypertrophic, anti-apoptotic, angiogenic, wound healing and vasodilator) properties. This review will outline the organ-specific and general anti-fibrotic significance of exogenously administered relaxin and its mechanisms of action that have been documented in various non-reproductive organs such as the cardiovascular system, kidney, lung, liver, skin and tendons. In addition, it will outline the influence of sex on relaxin's anti-fibrotic actions, highlighting its potential as an emerging anti-fibrotic therapeutic. Linked Articles: This article is part of a themed section on Recent Progress in the Understanding of Relaxin Family Peptides and their Receptors. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.10/issuetoc.",
author = "Samuel, {C. S.} and Royce, {S. G.} and Hewitson, {T. D.} and Denton, {K. M.} and Cooney, {T. E.} and Bennett, {Robert G}",
year = "2017",
month = "1",
day = "1",
doi = "10.1111/bph.13529",
language = "English (US)",
volume = "174",
pages = "962--976",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Anti-fibrotic actions of relaxin

AU - Samuel, C. S.

AU - Royce, S. G.

AU - Hewitson, T. D.

AU - Denton, K. M.

AU - Cooney, T. E.

AU - Bennett, Robert G

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Fibrosis refers to the hardening or scarring of tissues that usually results from aberrant wound healing in response to organ injury, and its manifestations in various organs have collectively been estimated to contribute to around 45–50% of deaths in the Western world. Despite this, there is currently no effective cure for the tissue structural and functional damage induced by fibrosis-related disorders. Relaxin meets several criteria of an effective anti-fibrotic based on its specific ability to inhibit pro-fibrotic cytokine and/or growth factor-mediated, but not normal/unstimulated, fibroblast proliferation, differentiation and matrix production. Furthermore, relaxin augments matrix degradation through its ability to up-regulate the release and activation of various matrix-degrading matrix metalloproteinases and/or being able to down-regulate tissue inhibitor of metalloproteinase activity. Relaxin can also indirectly suppress fibrosis through its other well-known (anti-inflammatory, antioxidant, anti-hypertrophic, anti-apoptotic, angiogenic, wound healing and vasodilator) properties. This review will outline the organ-specific and general anti-fibrotic significance of exogenously administered relaxin and its mechanisms of action that have been documented in various non-reproductive organs such as the cardiovascular system, kidney, lung, liver, skin and tendons. In addition, it will outline the influence of sex on relaxin's anti-fibrotic actions, highlighting its potential as an emerging anti-fibrotic therapeutic. Linked Articles: This article is part of a themed section on Recent Progress in the Understanding of Relaxin Family Peptides and their Receptors. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.10/issuetoc.

AB - Fibrosis refers to the hardening or scarring of tissues that usually results from aberrant wound healing in response to organ injury, and its manifestations in various organs have collectively been estimated to contribute to around 45–50% of deaths in the Western world. Despite this, there is currently no effective cure for the tissue structural and functional damage induced by fibrosis-related disorders. Relaxin meets several criteria of an effective anti-fibrotic based on its specific ability to inhibit pro-fibrotic cytokine and/or growth factor-mediated, but not normal/unstimulated, fibroblast proliferation, differentiation and matrix production. Furthermore, relaxin augments matrix degradation through its ability to up-regulate the release and activation of various matrix-degrading matrix metalloproteinases and/or being able to down-regulate tissue inhibitor of metalloproteinase activity. Relaxin can also indirectly suppress fibrosis through its other well-known (anti-inflammatory, antioxidant, anti-hypertrophic, anti-apoptotic, angiogenic, wound healing and vasodilator) properties. This review will outline the organ-specific and general anti-fibrotic significance of exogenously administered relaxin and its mechanisms of action that have been documented in various non-reproductive organs such as the cardiovascular system, kidney, lung, liver, skin and tendons. In addition, it will outline the influence of sex on relaxin's anti-fibrotic actions, highlighting its potential as an emerging anti-fibrotic therapeutic. Linked Articles: This article is part of a themed section on Recent Progress in the Understanding of Relaxin Family Peptides and their Receptors. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.10/issuetoc.

UR - http://www.scopus.com/inward/record.url?scp=85018062266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018062266&partnerID=8YFLogxK

U2 - 10.1111/bph.13529

DO - 10.1111/bph.13529

M3 - Article

C2 - 27250825

AN - SCOPUS:85018062266

VL - 174

SP - 962

EP - 976

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 10

ER -